Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.

Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.

PMID:
27617661
2.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A.

N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.

3.

Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Burger RA, Brady MF, Rhee J, Sovak MA, Kong G, Nguyen HP, Bookman MA.

Gynecol Oncol. 2013 Oct;131(1):21-6. doi: 10.1016/j.ygyno.2013.07.100. Epub 2013 Jul 29.

4.

Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).

Aisner J, Manola JB, Dakhil SR, Stella PJ, Sovak MA, Schiller JH.

J Thorac Oncol. 2013 Aug;8(8):1075-83. doi: 10.1097/JTO.0b013e3182937317.

5.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR.

J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.

6.

Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.

Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M, Levinson K, Lin H, Kane M, Gounder M, Lin Y, Shih WJ, White E, Rubin EH, Karantza V.

Mol Cancer Ther. 2011 Aug;10(8):1509-19. doi: 10.1158/1535-7163.MCT-10-0944. Epub 2011 Jun 16.

7.

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors.

Simon GR, Ilaria RL Jr, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, Wagner MM, de Alwis DP, Slapak CA, Miller MA, Spriggs DR.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1233-41. doi: 10.1007/s00280-011-1593-0. Epub 2011 Mar 23.

8.

Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study.

Sovak MA, Dupont J, Hensley ML, Ishill N, Gerst S, Abu-Rustum N, Anderson S, Barakat R, Konner J, Poyner E, Sabbatini P, Spriggs DR, Aghajanian C.

Int J Gynecol Cancer. 2007 Jan-Feb;17(1):197-203.

PMID:
17291253
9.

Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.

Sovak MA, Lutzker S, Zheng L, Guensch L, Joyce M, Schwartz S, Wu Y, Aisner J.

Lung Cancer. 2006 Aug;53(2):177-81. Epub 2006 Jun 21.

PMID:
16790293
10.

Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.

Sovak MA, Hensley ML, Dupont J, Ishill N, Alektiar KM, Abu-Rustum N, Barakat R, Chi DS, Sabbatini P, Spriggs DR, Aghajanian C.

Gynecol Oncol. 2006 Nov;103(2):451-7. Epub 2006 May 3.

PMID:
16677690
11.

Resveratrol and its glycon piceid are stable polyphenols.

Prokop J, Abrman P, Seligson AL, Sovak M.

J Med Food. 2006 Spring;9(1):11-4.

PMID:
16579722
12.

Iosimenol, a low-viscosity nonionic dimer: preclinical physicochemistry, pharmacology, and pharmacokinetics.

Sovak M, Terry R, Abramjuk C, Faberová V, Fiserova M, Laznicek M, Leuschner J, Malinak J, Zahradnik P, Masner O, Seligson A.

Invest Radiol. 2004 Mar;39(3):171-81.

PMID:
15076009
13.

No difference among modern contrast media's effect on neointimal proliferation and restenosis after coronary stenting in pigs.

Clauss W, Scheller B, Schmitt A, Sovak M, Speck U.

Invest Radiol. 2003 Dec;38(12):743-9.

PMID:
14627891
14.

Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model.

Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Böhm M, Stoll HP.

Eur Heart J. 2003 Aug;24(15):1462-7.

PMID:
12909076
15.

Grape Extract, Resveratrol, and Its Analogs: A Review.

Sovak M.

J Med Food. 2001 Summer;4(2):93-105.

PMID:
12639418
16.

Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.

Arsura M, Panta GR, Bilyeu JD, Cavin LG, Sovak MA, Oliver AA, Factor V, Heuchel R, Mercurio F, Thorgeirsson SS, Sonenshein GE.

Oncogene. 2003 Jan 23;22(3):412-25.

PMID:
12545162
17.

Herbal composition PC-SPES for management of prostate cancer: identification of active principles.

Sovak M, Seligson AL, Konas M, Hajduch M, Dolezal M, Machala M, Nagourney R.

J Natl Cancer Inst. 2002 Sep 4;94(17):1275-81.

PMID:
12208892
18.

Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience.

Sovak M, Seligson AL, Kucerova R, Bienova M, Hajduch M, Bucek M.

Dermatol Surg. 2002 Aug;28(8):678-85. Erratum in: Dermatol Surg 2002 Oct;28(8):following 970.

PMID:
12174057
19.

Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting.

Scheller B, Speck U, Schmitt A, Clauss W, Sovak M, Böhm M, Stoll HP.

Invest Radiol. 2002 Jan;37(1):29-34.

PMID:
11753151
20.

A new prodrug of paclitaxel: synthesis of Protaxel.

Seligson AL, Terry RC, Bressi JC, Douglass JG 3rd, Sovak M.

Anticancer Drugs. 2001 Apr;12(4):305-13.

PMID:
11335786
21.

Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells.

Kim DW, Sovak MA, Zanieski G, Nonet G, Romieu-Mourez R, Lau AW, Hafer LJ, Yaswen P, Stampfer M, Rogers AE, Russo J, Sonenshein GE.

Carcinogenesis. 2000 May;21(5):871-9.

PMID:
10783306
22.
23.

Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.

Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE.

J Clin Invest. 1997 Dec 15;100(12):2952-60.

24.

The Harry W. Fischer Lecture Session. Contrast Media: a meandering look.

Sovak M.

Acad Radiol. 1996 Aug;3 Suppl 2:S241-7. No abstract available.

PMID:
8796572
25.

Blood pool radiopaque polymers. Design considerations.

Sovak M, Douglass JG 3rd, Terry RC, Brown JW, Bakir F, Wasden TS.

Invest Radiol. 1994 Jun;29 Suppl 2:S271-4. No abstract available.

PMID:
7928254
26.

Contrast media: a journey almost sentimental.

Sovak M.

Invest Radiol. 1994 May;29 Suppl 1:S4-14. Review. No abstract available.

PMID:
8071043
28.

Exploration of the functional significance of the stilbene disulfonate binding site in mouse band 3 by site-directed mutagenesis.

Passow H, Wood PG, Lepke S, Müller H, Sovak M.

Biophys J. 1992 Apr;62(1):98-100. No abstract available.

29.

Neuroendocrine regulation of immunity: the effects of noradrenaline in Xenopus laevis, the South African clawed toad.

Clothier RH, Ruben LN, Johnson RO, Parker K, Sovak M, Greenhalgh L, Ooi EE, Balls M.

Int J Neurosci. 1992 Jan;62(1-2):123-40.

PMID:
1364139
30.

Iodinated contrast media. State of the art and the thorny path toward reduction of osmolality.

Sovak M.

Invest Radiol. 1991 Nov;26 Suppl 1:S2-4; discussion S15. No abstract available.

PMID:
1808128
31.

Primary carboxamides. Nonionic isotonic monomers.

Sovak M, Terry RC, Douglass JG, Schweitzer L.

Invest Radiol. 1991 Nov;26 Suppl 1:S159-61; discussion S165-6. No abstract available.

PMID:
1808115
32.

Ioxilan. Initial clinical observations.

Callantine MR, Sovak M, Lu HP.

Invest Radiol. 1990 Sep;25 Suppl 1:S107-8. No abstract available.

PMID:
2283219
33.

Ioxilan, a third generation low osmolality nonionic contrast medium. Systemic and renal hemodynamic effects.

Katzberg RW, Donahue LA, Morris TW, Ventura JA, Krutchen AE, Proskin HM, Sovak M, Cos LR.

Invest Radiol. 1990 Jan;25(1):46-51.

PMID:
2404899
34.

Current contrast media and ioxilan. Comparative evaluation of vascular pain by aversion conditioning.

Sovak M, Halkovich CA, Foster SJ.

Invest Radiol. 1988 Sep;23 Suppl 1:S84-7.

PMID:
3198369
35.

Isomerism in iohexol and ioxilan. Analysis and implications.

Foster SJ, Sovak M.

Invest Radiol. 1988 Sep;23 Suppl 1:S106-9.

PMID:
3198329
36.

The need for improved contrast media. Ioxilan: updating design theory.

Sovak M.

Invest Radiol. 1988 Sep;23 Suppl 1:S79-83.

PMID:
3058636
37.

Selective transcervical fallopian tube catheterization: technique update.

Rösch J, Thurmond AS, Uchida BT, Sovak M.

Radiology. 1988 Jul;168(1):1-5.

PMID:
3380948
38.

Radiographic contrast media, function and future reassessed.

Sovak M.

Int J Rad Appl Instrum B. 1988;15(1):3-7. No abstract available.

PMID:
3350693
39.

Intravenous injection of ioxilan, iohexol and diatrizoate. Effects on urine profiles in the rat.

Thomsen HS, Dorph S, Mygind T, Sovak M, Nielsen H, Rygaard H, Larsen S, Skaarup P, Hemmingsen L, Holm J.

Acta Radiol. 1988 Jan-Feb;29(1):131-6.

PMID:
2964835
40.

Brain changes on computed tomography following metrizamide myelography. Significance and therapeutic implications.

Centeno RS, Sovak M, Hackney DB, Garfin SR.

Spine (Phila Pa 1976). 1986 Jul-Aug;11(6):509-12.

PMID:
3787318
41.

Investigation of a new arthrographic contrast agent: Iotrol.

Guerra J Jr, Resnick D, Haghighi P, Sovak M, Cone R.

Invest Radiol. 1984 May-Jun;19(3):228-34.

PMID:
6469527
42.

Iotrol, a new myelographic agent: 2. Comparative electroencephalographic evaluation by spectrum analysis.

Sovak M, Ranganathan R, Kerber CW, Bickford R, Alksne JF.

AJNR Am J Neuroradiol. 1983 May-Jun;4(3):319-22.

PMID:
6410733
43.

Iotrol, a new myelographic agent: 1. Radiography, CT, CSF clearance, and brain penetration.

Kerber CW, Sovak M, Ranganathan RS, Heilman CB.

AJNR Am J Neuroradiol. 1983 May-Jun;4(3):317-8.

PMID:
6410732
44.

Experience with metrizamide in patients with previous severe anaphylactoid reactions to ionic contrast agents.

Rapoport S, Bookstein JJ, Higgins CB, Carey PH, Sovak M, Lasser EC.

Radiology. 1982 May;143(2):321-5.

PMID:
7071332
45.

Evaluation of intrathecal contrast media by aversion conditioning in rats.

Sovak M, Deutsch JA, Ranganathan R.

Invest Radiol. 1982 Jan-Feb;17(1):101-6.

PMID:
6896198
46.

Nonionic dimer: development and initial testing of an intrathecal contrast agent.

Sovak M, Ranganathan R, Speck U.

Radiology. 1982 Jan;142(1):115-8.

PMID:
6895557
47.

Development and preliminary pharmacologic evaluation of a zwitterionic oral cholecystographic agent.

Sovak M, Barnhart JL, Ranganathan R, Schulze PE, Siefert HM, Speck U.

Invest Radiol. 1981 Nov-Dec;16(6):513-6.

PMID:
7319759
48.

Determination of lethal dose in a protozoa: screening of contrast media toxicity.

Sovak M, Ranganathan R, Mutzel W.

Invest Radiol. 1981 Sep-Oct;16(5):438-42.

PMID:
7287357
49.

Mechanism of the biofeedback therapy of migraine: volitional manipulation of the psychophysiological background.

Sovak M, Kunzel M, Sternbach RA, Dalessio DJ.

Headache. 1981 May;21(3):89-92. No abstract available.

PMID:
7263222
50.

Release of serotonin from human platelets in vitro by radiographic contrast media.

Ring J, Sovak M.

Invest Radiol. 1981 May-Jun;16(3):245-8.

PMID:
7053228

Supplemental Content

Support Center